Investors & Media
Sunesis is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics for oncology. Our experienced cancer drug development organization is committed to advancing voreloxin through clinical trials. Sunesis' lead compound, voreloxin, is currently being evaluated as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer, in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeoloid leukemia (AML) patients unlikely to benefit from standard induction chemotherapy and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.
In addition, Sunesis has formed strategic research and drug discovery partnerships with leading pharmaceutical and biopharmaceutical companies, including Biogen Idec Inc.and SARcode Corporation.
| NASDAQ:SNSS | ANNUAL REPORT | ||||||||||
Market data powered by eSignal. |
2008 Annual Report and Form 10-K
( PDF, 1.5 MB) |
||||||||||
| CORPORATE PRESENTATION | |||||||||||
|
Corporate_Presentation.pdf
( PDF, 502.6 KB) |
|||||||||||
ChangeLatest News
Jan 21, 2010
Sunesis Completes Enrollment of Voreloxin Phase 1b/2 Combination Trial in Acute Myeloid LeukemiaCalendar of Events
Mar 10, 2010 at 8:45 AM ET
Cowen and Company 30th Annual Healthcare Conference
